Glucagon-like peptide-1 receptor agonists and risk for cardiovascular events in older adults treated with levothyroxine: a target trial emulation

Fanxing Du, Naykky M Singh Ospina, Yishan Chen, Juan P Brito, Qing Liu, Stephan Schmidt, Rozalina G McCoy, Brian Cicali, Hui Shao, Tianze Jiao · 2025

Read Glucagon-like peptide-1 receptor agonists and risk for cardiovascular events in older adults treated with levothyroxine: a target trial emulation by Fanxing Du, Naykky M Singh Ospina, Yishan Chen, Juan P Brito, Qing Liu, Stephan Schmidt, Rozalina G McCoy, Brian Cicali, Hui Shao, Tianze Jiao (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12729143.txt.

Description

Fanxing Du and co-authors ask whether a popular diabetes drug class raises heart rhythm risk in older patients on thyroid medicine, in a 2025 study. The drugs can lower the needed thyroid dose, and too much thyroid hormone can trigger irregular heartbeat and stroke.

Using a method that mimics a clinical trial in real records, the team matched new users of the diabetes drugs against users of a rival class. All were Medicare patients over sixty five, on a stable thyroid dose for at least six months, with no cancer or palliative care in the prior year. Outcomes were new atrial fibrillation or flutter, and stroke. The design aims at a fair head to head safety comparison.

Catalog record

CREATORFanxing Du, Naykky M Singh Ospina, Yishan Chen, Juan P Brito, Qing Liu, Stephan Schmidt, Rozalina G McCoy, Brian Cicali, Hui Shao, Tianze Jiao
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE40 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12729143

Browse the full library · About the Tower of Babel